CIK 0001326190
- Non-accelerated filer
- Smaller reporting company
Altimmune, Inc.
Sign in to watch- Ticker
- ALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 202726770
- Phone
- +1 862-457-1450
- Business address
- 350 MOUNT KEMBLE AVENUE, SUITE 1001, MORRISTOWN, NJ, 07960
- Former names
- PHARMATHENE, INC, HEALTHCARE ACQUISITION CORP
- 4 Open-market buy Director bought 300 shares at $2.88 ($863)
- 4 Grant or award President and CEO acquired 126 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 1,825 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 691 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 568 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 1,832 shares (grant or award)
- 4 Open-market sale Director sold 2,714 shares at $15.00 ($40,710)
- 4 Open-market buy Director bought 9,000 shares at $4.27 ($38,430)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Chief Financial Officer bought 10,000 shares at $4.31 ($43,140)
- 4 Open-market buy Chief Medical Officer bought 10,000 shares at $4.22 ($42,200)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 2,375 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 2,364 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 8,422 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 2,183 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 2,183 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 7,658 shares (to pay taxes)
- 4 Grant or award Chief Financial Officer acquired 1,172 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 7 of 34 · 674 filings